Abstracts

ARV PENETRATION INTO FEMALE GENITAL TRACT DURING PREGNANCY: EFAVIRENZ AS A CASE STUDY

Proper characterisation of antiretroviral pharmacokinetics in the female genital tract is crucial in developing effective pre-exposure prophylaxis and prevention of intrapartum mother-to-child transmission interventions. Progress in this area has been limited by sampling constraints. A novel assay to quantify efavirenz in cervicovaginal fluid from flocked swabs using LC-MS/MS was developed and validated as per FDA…

GENITAL INFLAMMATION DOES NOT DECREASE VAGINAL TFV LEVELS IN WOMEN TAKING ORAL PREP

African studies demonstrate that genital inflammation decreases tenofovir (TFV) gel’s efficacy. We evaluated the impact of inflammation and dysbiosis on cervicovaginal fluid (CVF) TFV concentrations in US women taking oral TDF/FTC for PrEP. Southern Californian women on oral TDF/FTC in the Adherence Enhancement Guided by Individualized Texting and Drug Levels (AEGiS) study had CVF collected…

PRENATAL EFAVIRENZ EXPOSURE INDEPENDENTLY ASSOCIATED WITH FOETAL CYP2B6 GENOTYPE

Understanding the influence of foetal and maternal genetics on prenatal drug exposure could play an important role in assessing observed risk-benefit differentials during pregnancy. In this sub-study of VADICT (NCT03284645), the influence of functional CYP2B6 polymorphisms on prenatal exposure to efavirenz was investigated. VADICT is a cohort study that started recruiting in June 2017 in…

A CROSS-SECTIONAL ANALYSIS OF ANTIRETROVIRAL REGIMEN ACTIVITY IN CEREBROSPINAL FLUID

ACTG A5321 is a prospective cohort study of changes in HIV-1 reservoirs among participants with HIV on antiretroviral therapy (ART). We designed a single cross-sectional analysis of antiretroviral (ARV) pharmacokinetics (PK) in cerebrospinal fluid (CSF) and investigated relationships among a novel putative measure of ART regimen CSF activity and concurrent biomarkers of HIV persistence and…